Dental Tribune Europe
This year, Straumann’s revenues for the first nine months have exceeded 1 billion Swiss francs. (Image: Straumann Group)

Straumann results bolstered by implants and aligners

By Jeremy Booth, Dental Tribune International
October 30, 2019

BASEL, Switzerland: The Straumann Group has lifted its outlook for organic revenue growth for 2019 after a strong performance in the third quarter. In the company’s financial report for the quarter, it hailed the North American launch of its BLX implant as a major highlight of the period and said that implants and restorative products had been its largest source of growth.

Straumann launched its premium BLX implant in the Europe, Middle East and Africa (EMEA) markets in the first half and said in July that it had sold more than 30,000 BLX implants over the six-month period. The fully tapered premium implant system was launched in the North American market in the third quarter and full market launches for the implant are imminent in all key Straumann markets except for China, Japan, Russia and Turkey. Volumes for the quarter were not provided, but the company said that BLX had attracted hundreds of new customers in the past six months—many of whom had purchased the company’s apically tapered BLT implant line. Non-premium implants continued to outpace Straumann’s premium implant portfolio in the third quarter and were boosted by the continuing international roll-out of the upper value implant brand Neodent.

Growth in the company’s digital business was driven by an expansion of clear aligner sales. Straumann noted that new clear aligner cases started in North America had increased by 60% and that investments were being made to up the company’s production capacity for clear aligners in the US, Brazil and Germany. Straumann said that it had gained access to new high-performance multilayer thermoplastics during the third quarter by acquiring California-based Bay Materials, which specialises in the development and supply of thermoplastics for orthodontic applications.

Straumann said that it had struggled to meet demand for its intra-oral scanners in the quarter and that its dental service organisation business had exhibited strong growth.

Straumann’s financial performance

The company posted CHF 371.1 million (€336.1 million) in sales for the third quarter and CHF 1.151 billion for the nine-month period ending on 30 September. This was the first time that Straumann had seen nine-month revenues exceed CHF 1 billion.

In the third quarter, organic revenue growth, which excludes headwinds from currencies and the effects of acquisitions, increased by 18.7%. Double-digit increases in organic revenue growth were posted for all the regions in which the company operates. In the EMEA region—which accounts for the largest slice of the group—organic revenue was CHF 142.6 million, up 13.1% year on year; the increase was 23.5% in North America, 23.4% in Asia Pacific and 17.3% in Latin America.

“The company said that North America, which accounted for just over 30% of Straumann revenues in the nine-month period, had edged ahead of Asia Pacific as the company’s fastest-growing region.”

For the nine-month period, organic revenue growth increased by 17.1%. The EMEA region accounted for 41.5% of the group’s revenues in this period, and organic revenue growth increased by 13.5% in the EMEA region, by 19.9% in North America, by 19.4% in Asia Pacific and by 18.1% in Latin America. The company said that North America, which accounted for just over 30% of Straumann revenues in the nine-month period, had edged ahead of Asia Pacific as the company’s fastest-growing region.

CEO Marco Gadola said, “Successful product launches, our fast-growing clear aligner business, the international roll-out of our value brands, and supply agreements with large dental chains all contributed to our continuing strong growth. A major highlight in Q3 was the launch of our innovative Straumann BLX implant system in North America. This next-generation implant, together with Neodent GM and Anthogyr Axiom PX, gives us full access to the fully tapered implant segment and positions us to become a leading global provider of immediacy solutions.”

Gadola said the company had lifted its outlook for full-year organic revenue growth to a percentage ranging in the mid-teens.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2019 - All rights reserved - Dental Tribune International